Haleon plc Form 6-K Summary
Business context and reporting period
Haleon plc filed this Form 6-K for May 2024. The filing reports the publication of an updated base prospectus for the company’s Euro Medium Term Note (EMTN) programme and does not present quarterly or annual operating results.
Haleon is a global consumer-health company with products across oral health, pain relief, respiratory health, digestive health, vitamins, minerals and supplements, and other categories.
Financing and key information
- The base prospectus, dated 3 May 2024, relates to a £10.0 billion EMTN programme.
- The programme is used by Haleon UK Capital plc and Haleon Netherlands Capital B.V.
- The notes issued under the programme are guaranteed by Haleon plc.
- The prospectus was published following a routine annual update.
- The filing provides no new revenue, profit, cash flow, margin, debt-balance, liquidity, or other operating-performance figures.
Material changes versus the prior comparable period
The filing does not provide a comparable-period financial update. The only reported change is the routine annual update and publication of the 3 May 2024 base prospectus.
Guidance, outlook, risks and unusual items
No earnings guidance or operational outlook is provided. Investors should review the base prospectus for the detailed terms, risk factors, guarantees, applicable jurisdictions, and offering restrictions associated with the EMTN programme.
The company states that information in the base prospectus may be intended only for residents of specified countries and should not be relied upon by persons outside the intended jurisdictions.
Facts investors should verify
- Review the full 3 May 2024 base prospectus on Haleon’s debt-investor website.
- Confirm the terms and conditions of any individual notes issued under the £10.0 billion programme.
- Assess Haleon plc’s guarantee obligations and the credit risks of the issuing subsidiaries.
- Confirm whether access and offering restrictions apply based on the investor’s jurisdiction.